Product Description

TESLASCAN is a liver-specific contrast agent approved for sale in the U.S. in November 1997. Its introduction expands the Amersham Health portfolio to include an organ-specific MR agent. When injected intravenously, TESLASCAN aids in the detection, localization, characterization, and evaluation of liver lesions. Imaging can begin within minutes of injection, and additional scans can be taken up to 24 hours later without reinjection or loss of image quality.

Malignancy cannot be distinguished by the pattern of enhancement, or by the presence or absence of enhancement. The most common adverse events in clinical trials were injection site discomfort (67%), nausea (11%), headache (5%), vomiting (3%), and abdominal pain (2%). Caution should be exercised before administering TESLASCAN to patients who have or cannot tolerate abdominal pain, nausea, or vomiting. The possibility of nausea and vomiting should be considered when administering TESLASCAN Injection to patients who cannot tolerate vomiting, who have reflux esophagitis, or who cannot be repositioned to prevent aspiration.